Skip to content
Register Sign in Wishlist
Pharmaceutical Innovation

Pharmaceutical Innovation
Incentives, Competition, and Cost-Benefit Analysis in International Perspective


Frank A. Sloan, Chee-Ruey Hsieh, Uwe Reinhardt, William Comanor, Aidan Hollis, Stephen M. Maurer, Charles Eesley, Frank Lichtenberg, Henry Grabowski, Ernst Berndt, Mark Pauly, Michael Drummond, Pierre Cremieux, Denise Jarvinen, Genia Long, Phi Merrigan, Kuang-Ta Vance Lo, Yichen Hong, Ya-Chen Tina Shih
View all contributors
  • Date Published: April 2007
  • availability: Temporarily unavailable - available from TBC
  • format: Hardback
  • isbn: 9780521874908

$ 79.99

Temporarily unavailable - available from TBC
Notify me when available Add to wishlist

Other available formats:

Looking for an evaluation copy?

This title is not currently available for evaluation. However, if you are interested in the title for your course we can consider offering an evaluation copy. To register your interest please contact providing details of the course you are teaching.

Product filter button
About the Authors
  • The pharmaceutical industry worldwide is a rapidly burgeoning industry contributing to growth of gross domestic product and employment. Technological change in this field has been very rapid, with many new products being introduced. For this reason in part, health care budgets throughout the world have increased dramatically, eliciting growing pressures for cost containment. This book explores four important issues in pharmaceutical innovations: (1) the industry structure of pharmaceutical innovation; (2) incentives for correcting market failures in allocating resources for research and development; (3) competition and marketing; and (4) public evaluation of the benefits and costs of innovation. The lessons are applicable to countries all over the world, at all levels of economic development. By discussing existing evidence this book proposes incentive arrangements to accomplish social objectives.

    • Includes chapters by leading authorities on the economics of pharmaceuticals, e.g. U. Reinhardt, F. Lichtenberg, H. Grabowski, E. Berndt and M. Pauly
    • Discussions of research findings are up-to-date; many concepts are presented that will give the book a long shelf-life
    • Presentations are not country-centric but are applicable to countries at all levels of economic development
    Read more

    Customer reviews

    Not yet reviewed

    Be the first to review

    Review was not posted due to profanity


    , create a review

    (If you're not , sign out)

    Please enter the right captcha value
    Please enter a star rating.
    Your review must be a minimum of 12 words.

    How do you rate this item?


    Product details

    • Date Published: April 2007
    • format: Hardback
    • isbn: 9780521874908
    • length: 346 pages
    • dimensions: 236 x 160 x 26 mm
    • weight: 0.602kg
    • contains: 12 tables
    • availability: Temporarily unavailable - available from TBC
  • Table of Contents

    1. Introduction Frank Sloan and Chee-Ruey Hsieh
    Part I. The Industry Structure of Pharmaceutical Innovation:
    2. The pharmaceutical sector in health care Uwe Reinhardt
    3. The economics of research and development in the pharmaceutical industry William Comanor
    Part II. Structuring Incentives for Research and Development:
    4. Drugs for neglected diseases: new incentives for innovation Aidan Hollis
    5. When patents fail: finding new drugs for the developing world Stephen M. Maurer
    6. Implementing a public subsidy for vaccines Frank Sloan and Charles Eesley
    7. Ensuring the future supply of vaccines: is a National Vaccine Authority the answer? Frank Lichtenberg
    Part III. Competition and Marketing:
    8. Competition between generic and branded drugs Henry Grabowski
    9. The United States' experience with direct-to-consumer advertising of prescription drugs: what have we learned? Ernst Berndt
    Part IV. Public Evaluation of the Benefits and Costs of Innovation:
    10. Measures of costs and benefits for drugs in cost effectiveness analysis Mark Pauly
    11. Using economic evaluation in reimbursement decisions for health technologies: lessons from international experience Michael Drummond
    12. Pharmaceutical spending and health outcomes Pierre Cremieux, Denise Jarvinen, Genia Long and Phi Merrigan
    13. Pharmaceutical innovation and health outcomes: empirical evidence from Taiwan Chee-Ruey Hsieh, Kuang-Ta Vance Lo, Yichen Hong and Ya-Chen Tina Shih
    14. Conclusions and policy implications Frank A. Sloan and Chee-Ruey Hsieh.

  • Editors

    Frank A. Sloan, Duke University, North Carolina
    Frank Sloan has been the J. Alexander McMahon Professor of Health Policy and Management and Professor of Economics at Duke University since 1993, where he holds faculty appointments in the Department of Economics, the School of Public Policy, the Fuqua School of Business, and the School of Nursing. Before joining the faculty at Duke, he was a research economist at the Rand Corporation and served on the faculties of the University of Florida and Vanderbilt University. His current research interests include alcohol use and smoking prevention, long-term care, medical malpractice, and cost-effectiveness analyses of medical technologies. Professor Sloan also has a long-standing interest in hospitals, health care financing, and health manpower. He has served on several national advisory public and private groups, including the Physician Payment Review Commission. He has been a member of the Institute of Medicine of the National Academy of Sciences since 1982, recently chairing IOM committees on vaccine financing and cancer in low- and middle-income countries. He recently received a Merit Award from the National Institutes of Health and an Investigator Award from the Robert Wood Johnson Foundation. Professor Sloan's most recent books include The Smoking Puzzle: Information, Risk Perceptions, and Choice (2003) with Drs V. Kerry Smith and Donald H. Taylor, Jr., and The Price of Smoking with Drs Jan Ostermann, Gabriel Picone, Christopher Conover, and Donald H. Taylor, Jr. (2004). Professor Sloan received his Ph.D. in economics from Harvard University in 1969.

    Chee-Ruey Hsieh, Academia Sinica, Taipei, Taiwan
    Chee-Ruey Hsieh is a Research Fellow in the Institute of Economics at Academia Sinica, Taipei, Taiwan. He received his Ph.D. in economics from Vanderbilt University in 1990. Dr Hsieh has a long-standing interest in health economics and health policy. He is the coeditor of two other books: The Economic Analysis of Substance Use and Abuse, and The Economics of Health Care in Asia-Pacific Countries.


    Frank A. Sloan, Chee-Ruey Hsieh, Uwe Reinhardt, William Comanor, Aidan Hollis, Stephen M. Maurer, Charles Eesley, Frank Lichtenberg, Henry Grabowski, Ernst Berndt, Mark Pauly, Michael Drummond, Pierre Cremieux, Denise Jarvinen, Genia Long, Phi Merrigan, Kuang-Ta Vance Lo, Yichen Hong, Ya-Chen Tina Shih

Sign In

Please sign in to access your account


Not already registered? Create an account now. ×

Sorry, this resource is locked

Please register or sign in to request access. If you are having problems accessing these resources please email

Register Sign in
Please note that this file is password protected. You will be asked to input your password on the next screen.

» Proceed

You are now leaving the Cambridge University Press website. Your eBook purchase and download will be completed by our partner Please see the permission section of the catalogue page for details of the print & copy limits on our eBooks.

Continue ×

Continue ×

Continue ×

Find content that relates to you

Join us online

This site uses cookies to improve your experience. Read more Close

Are you sure you want to delete your account?

This cannot be undone.


Thank you for your feedback which will help us improve our service.

If you requested a response, we will make sure to get back to you shortly.

Please fill in the required fields in your feedback submission.